[go: up one dir, main page]

LT4736B - Farmacinės kompozicijos, turinčios plazmos proteino - Google Patents

Farmacinės kompozicijos, turinčios plazmos proteino Download PDF

Info

Publication number
LT4736B
LT4736B LT2000018A LT2000018A LT4736B LT 4736 B LT4736 B LT 4736B LT 2000018 A LT2000018 A LT 2000018A LT 2000018 A LT2000018 A LT 2000018A LT 4736 B LT4736 B LT 4736B
Authority
LT
Lithuania
Prior art keywords
water
product
pharmaceutical composition
serum albumin
plasma
Prior art date
Application number
LT2000018A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT2000018A (en
Inventor
Lajos Hegedues
Krisztina Krempels
Krisztina Paal
Gabor Petho
Original Assignee
Human Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Rt. filed Critical Human Rt.
Publication of LT2000018A publication Critical patent/LT2000018A/xx
Publication of LT4736B publication Critical patent/LT4736B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
LT2000018A 1997-09-18 2000-03-17 Farmacinės kompozicijos, turinčios plazmos proteino LT4736B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU9701554A HUP9701554D0 (en) 1997-09-18 1997-09-18 Pharmaceutical composition containing plazma proteins

Publications (2)

Publication Number Publication Date
LT2000018A LT2000018A (en) 2000-08-25
LT4736B true LT4736B (lt) 2000-12-27

Family

ID=90014222

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2000018A LT4736B (lt) 1997-09-18 2000-03-17 Farmacinės kompozicijos, turinčios plazmos proteino

Country Status (33)

Country Link
US (5) US6743826B1 (zh)
EP (1) EP0981375B1 (zh)
JP (1) JP2001508806A (zh)
KR (1) KR100587962B1 (zh)
CN (1) CN1189216C (zh)
AR (1) AR017120A1 (zh)
AT (1) ATE230611T1 (zh)
AU (1) AU734695B2 (zh)
BG (1) BG64749B1 (zh)
BR (1) BR9812469A (zh)
CA (1) CA2269923C (zh)
CZ (1) CZ301326B6 (zh)
DE (1) DE69810612T2 (zh)
DK (1) DK0981375T3 (zh)
EA (1) EA004700B1 (zh)
ES (1) ES2187062T3 (zh)
HR (1) HRP980499A2 (zh)
HU (1) HUP9701554D0 (zh)
IL (1) IL135055A (zh)
LT (1) LT4736B (zh)
LV (1) LV12493B (zh)
NO (1) NO325294B1 (zh)
NZ (1) NZ503302A (zh)
PL (1) PL193067B1 (zh)
PT (1) PT981375E (zh)
RO (1) RO118695B1 (zh)
RS (1) RS50102B (zh)
SI (1) SI20189B (zh)
SK (1) SK284683B6 (zh)
TR (1) TR200001545T2 (zh)
TW (1) TWI222365B (zh)
WO (1) WO1999013914A1 (zh)
ZA (1) ZA988585B (zh)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US8137684B2 (en) * 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
WO2000047187A1 (en) * 1999-02-11 2000-08-17 Kinetana Inc. Serum albumin-based parenteral formulations of polyene macrolides
WO2001077137A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
ES2252048T3 (es) 1999-09-16 2006-05-16 Novo Nordisk A/S Composicion para fiv.
IL152180A0 (en) * 2000-04-10 2003-05-29 Teva Pharma Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
AU2001253336A1 (en) * 2000-04-10 2001-10-23 Teva Pharmaceutical Industries Ltd. Method 0f administration of paclitaxel-plasma protein formulation
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20020192280A1 (en) * 2001-05-01 2002-12-19 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
EP2277889B1 (en) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
CA2492297A1 (en) 2002-07-16 2004-01-22 Medexis S.A. Steroid conjugates, preparation thereof and the use thereof
GR1004274B (el) 2002-07-16 2003-06-23 Medexis ���� Συμπλοκα στεροειδων ορμονων με πρωτεινες: νεες ουσιες για την ειδικη ανιχνευση και καταστροφη καρκινικων κυτταρων προερχομενων απο στερεους ογκους και αιματολογικες κακοηθειες
JPWO2004024188A1 (ja) * 2002-09-12 2006-01-05 日本メジフィジックス株式会社 薬物の血漿蛋白質結合を制御するための製剤
LT1585548T (lt) 2002-12-09 2018-09-25 Abraxis Bioscience, Llc Farmakologinių agentų kompozicijos ir įvedimo būdai
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
US20050079546A1 (en) * 2003-05-01 2005-04-14 Dasa Lipovsek Serum albumin scaffold-based proteins and uses thereof
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
US20050277584A1 (en) * 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US8391959B2 (en) * 2004-09-29 2013-03-05 Tel Hashomer Medical Research Infrastructure And Services Ltd. Composition for improving efficiency of drug delivery
US20060198891A1 (en) 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
RU2283133C1 (ru) * 2005-06-03 2006-09-10 Общество С Ограниченной Ответственностью "Ферон" Лечебное средство
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
CA2683415C (en) 2007-04-04 2020-12-08 Sigmoid Pharma Limited An oral pharmaceutical composition
WO2008132707A1 (en) 2007-04-26 2008-11-06 Sigmoid Pharma Limited Manufacture of multiple minicapsules
US20110009497A1 (en) * 2008-03-21 2011-01-13 Fujifilm Corporation Drug-containing composition
CN101658516B (zh) * 2008-08-26 2011-10-05 齐鲁制药有限公司 紫杉醇类药物组合物及其制备方法
JP5640079B2 (ja) 2009-05-18 2014-12-10 シグモイド・ファーマ・リミテッドＳｉｇｍｏｉｄ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ 油滴含有組成物
BR112012002963A2 (pt) 2009-08-12 2017-10-24 Sigmoid Pharma Ltd composições imunomoduladoras compreendendo uma matriz de polímero e uma fase oleosa
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
US20110070293A1 (en) 2009-09-23 2011-03-24 Javeri Indu Methods for the Preparation of Liposomes Comprising Docetaxel
BR112012014962A2 (pt) * 2009-12-18 2016-04-05 Exodos Life Sciences Ltd Partnership métodos e composições para formulações líquidas e estáveis de fármacos
WO2011097149A2 (en) * 2010-02-03 2011-08-11 Oncbiomune, L.L.C. Taxane-and taxoid-protein compositions
AR093275A1 (es) 2010-03-17 2015-05-27 Centro De Excelencia En Productos Y Procesos De Cordoba (Ceprocor) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
ES2989832T3 (es) 2014-03-18 2024-11-27 Izun Pharmaceuticals Corp Composiciones de cannabinoides unidos a proteínas
ES2960598T3 (es) 2014-05-08 2024-03-05 Kiora Pharmaceuticals Gmbh Compuestos para el tratamiento de enfermedades y trastornos oftálmicos
EA036036B1 (ru) 2014-11-07 2020-09-16 Сигмойд Фарма Лимитед Композиции, содержащие циклоспорин
AR100034A1 (es) 2015-01-30 2016-09-07 Consejo Nac De Investig Científicas Y Técnicas (Conicet) Una composición farmacéutica soluble en agua que comprende, al menos, una sustancia terapéuticamente activa y, al menos, una sustancia con capacidad para formar micelas
WO2016182929A1 (en) * 2015-05-08 2016-11-17 Spectral Platforms, Inc. Albumin-based non-covalent complexes and methods of use thereof
CN107683134B (zh) 2015-05-15 2021-02-23 珠海贝海生物技术有限公司 多西他赛及人血清白蛋白复合物
US20180185308A1 (en) * 2015-06-18 2018-07-05 Matinas Biopharma Nanotechnologies, Inc. Compositions and methods for treating inflammatory disease or conditions
US20170128480A1 (en) * 2015-11-09 2017-05-11 Max A. Cayo Cardiac Glycosides for the Treatment of Hypercholesterolemia
ES2880482T3 (es) 2016-01-11 2021-11-24 Epicentrx Inc Composiciones y métodos para la administración intravenosa de 2-bromo-1-(3,3-dinitroazetidin-1-il)etanona
EP4019023A1 (en) * 2016-08-03 2022-06-29 Zhuhai Beihai Biotech Co., Ltd. Formulations of fosaprepitant and aprepitant
CN110062622B (zh) 2016-10-27 2022-10-14 珠海贝海生物技术有限公司 多西他赛和人血清白蛋白的中性pH组合物
RU2019131436A (ru) 2017-03-09 2021-04-10 Изун Фармасьютикалс Корп. Стабилизированные композиции связанных с белком каннабиоидов
WO2018175346A1 (en) 2017-03-20 2018-09-27 Spectral Platforms, Inc. Spectroscopic methods to detect and characterize microorganisms
CN111511350B (zh) 2017-07-07 2023-10-13 埃皮辛特瑞柯斯公司 用于治疗剂的肠胃外施用的组合物
US11510901B2 (en) 2018-01-08 2022-11-29 Epicentrx, Inc. Methods and compositions utilizing RRx-001 combination therapy for radioprotection
EP3761960B1 (en) * 2018-03-09 2023-11-22 Kiora Pharmaceuticals GmbH Ophthalmic formulation
EP3811982A1 (en) * 2019-10-25 2021-04-28 Université de Strasbourg Protein-based biomaterial with viscoelastic behaviour, process for obtaining it and uses thereof
CN118615273A (zh) 2020-02-04 2024-09-10 珠海贝海生物技术有限公司 多西他赛制剂
CN111529506B (zh) * 2020-05-18 2021-09-03 同济大学 一种两性霉素b白蛋白纳米制剂及其制备方法和应用
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
US12151045B2 (en) 2020-12-28 2024-11-26 Davol Inc. Reactive dry powdered hemostatic materials comprising a protein and a multifunctionalized modified polyethylene glycol based crosslinking agent
CN115997024A (zh) * 2021-06-29 2023-04-21 基因细胞生物技术公司 高效生产白蛋白的植物细胞株及其用途
CN114544926A (zh) * 2021-12-02 2022-05-27 浙江鑫科医疗科技有限公司 一种血清蛋白稳定剂
CN115236216B (zh) * 2022-06-07 2024-03-01 合肥和合医疗科技有限公司 高效液相色谱串联质谱检测全血中免疫抑制剂的试剂盒，其制备方法和检测方法
CN116212639A (zh) * 2023-02-28 2023-06-06 湖南科伦制药有限公司 一种去除药液中有机溶剂的方法及系统
CN116297963B (zh) * 2023-03-24 2024-12-27 四川汇宇制药股份有限公司 一种白蛋白结合型紫杉醇注射剂中辛酸钠含量的检测方法
CN120789284A (zh) * 2025-09-18 2025-10-17 通化安睿特生物制药股份有限公司 一种包载环孢菌素a的白蛋白结合型药物及制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58216126A (ja) 1982-06-11 1983-12-15 Ono Pharmaceut Co Ltd 可容化製剤
DE3702105A1 (de) 1987-01-24 1988-08-04 Bayer Ag Parenterale loesung
EP0326618A1 (en) 1987-03-04 1989-08-09 Nippon Hypox Laboratories Incorporated Medicinal composition containing albumin as carrier and process for its preparation
US5560933A (en) 1993-02-22 1996-10-01 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5621001A (en) 1992-08-03 1997-04-15 Bristol-Myers Squibb Company Methods for administration of taxol

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4833013A (zh) * 1971-08-30 1973-05-07
DE2653534C2 (de) * 1975-12-22 1986-08-28 Baxter Travenol Laboratories, Inc., Deerfield, Ill. Feste Antihämophilen-Faktor-Präparation und Verfahren zu ihrer Herstellung
JPS63215640A (ja) * 1987-03-04 1988-09-08 Nippon Hai Potsukusu:Kk 易吸収性抗炎症剤及びその製造方法
US5356927A (en) * 1992-12-02 1994-10-18 Thomas Jefferson University Methods of treating plasmodium and babesia parasitic infections
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
GB9510716D0 (en) * 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
TR199600775A2 (tr) 1996-09-27 1997-09-21 Tureks Turunc Madencilik Ic Ve Taslara eskitilmis görüntü kazandirilmasi icin bir yöntem.
US5776912A (en) * 1996-12-20 1998-07-07 Schering Corporation Lipophilic oligosaccharide antibiotic compositions
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58216126A (ja) 1982-06-11 1983-12-15 Ono Pharmaceut Co Ltd 可容化製剤
DE3702105A1 (de) 1987-01-24 1988-08-04 Bayer Ag Parenterale loesung
EP0326618A1 (en) 1987-03-04 1989-08-09 Nippon Hypox Laboratories Incorporated Medicinal composition containing albumin as carrier and process for its preparation
US5621001A (en) 1992-08-03 1997-04-15 Bristol-Myers Squibb Company Methods for administration of taxol
US5665761A (en) 1992-08-03 1997-09-09 Bristol-Myers Squibb Company Methods for administration of taxol
US5670537A (en) 1992-08-03 1997-09-23 Bristol-Meyers Squibb Company Method for effecting tumor regression with a low dose, short infusion taxol regimen
US5560933A (en) 1993-02-22 1996-10-01 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
EISEMAN, J.L. ET AL.: "Plasma pharmacokinetics and tissue distribution of Paclitaxel in CD2F1Mice", CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1994, pages 465 - 471
JOHANSEN K ET AL.: "Automated analysis of free and total concentrations of three antiepileptic drugs in plasma with on-line dialysis and high-performance liquid chromatography", J CHROMATOGR B BIOMED APPL., 1995, pages 292 - 298
PAVAN I ET AL.: "Monitoring propofol serum levels by rapid and sensitive reversed-phase high-performance liquid chromatography during prolonged sedation in ICU patients", J CHROMATOGR SCI., 1992, pages 164 - 166
ROWINSKY EK, CAZENAVE LA, DONEHOWER RC.: "Taxol: a novel investigational antimicrotubule agent", J NATL CANCER INST., 1990, pages 1247 - 1259, XP002054343, DOI: doi:10.1093/jnci/82.15.1247
THOMAS FT, TEPPER MA, THOMAS JM, HAISCH CE.: "15-Deoxyspergualin: a novel immunosuppressive drug with clinical potential", ANN. N. Y. ACAD. SCI., 1993, pages 175 - 192

Also Published As

Publication number Publication date
US7501455B2 (en) 2009-03-10
BG104245A (en) 2000-11-30
LV12493A (en) 2000-06-20
ZA988585B (en) 2000-03-13
NZ503302A (en) 2001-08-31
ATE230611T1 (de) 2003-01-15
NO20001371L (no) 2000-05-18
TR200001545T2 (tr) 2000-10-23
ES2187062T3 (es) 2003-05-16
PT981375E (pt) 2003-04-30
DE69810612D1 (de) 2003-02-13
JP2001508806A (ja) 2001-07-03
PL193067B1 (pl) 2007-01-31
HUP9701554D0 (en) 1997-11-28
US6743826B1 (en) 2004-06-01
CZ301326B6 (cs) 2010-01-20
CN1270529A (zh) 2000-10-18
BR9812469A (pt) 2002-02-05
US8946167B2 (en) 2015-02-03
AU9362398A (en) 1999-04-05
RS50102B (sr) 2009-01-22
NO325294B1 (no) 2008-03-17
CN1189216C (zh) 2005-02-16
KR100587962B1 (ko) 2006-06-13
EA004700B1 (ru) 2004-06-24
US7119124B2 (en) 2006-10-10
EA200000331A1 (ru) 2000-10-30
LV12493B (en) 2001-01-20
US20040014655A1 (en) 2004-01-22
BG64749B1 (bg) 2006-02-28
RO118695B1 (ro) 2003-09-30
YU16600A (sh) 2003-08-29
PL339369A1 (en) 2000-12-18
TWI222365B (en) 2004-10-21
DE69810612T2 (de) 2003-10-02
EP0981375B1 (en) 2003-01-08
SI20189A (sl) 2000-10-31
SK284683B6 (sk) 2005-09-08
IL135055A (en) 2004-09-27
KR20010052072A (ko) 2001-06-25
DK0981375T3 (da) 2003-05-05
AR017120A1 (es) 2001-08-22
US20050064028A1 (en) 2005-03-24
CA2269923C (en) 2003-07-22
CA2269923A1 (en) 1999-03-25
LT2000018A (en) 2000-08-25
AU734695B2 (en) 2001-06-21
SI20189B (sl) 2007-10-31
SK3292000A3 (en) 2000-08-14
NO20001371D0 (no) 2000-03-16
WO1999013914A1 (en) 1999-03-25
CZ2000952A3 (cs) 2000-09-13
US20070232536A1 (en) 2007-10-04
IL135055A0 (en) 2001-05-20
HRP980499A2 (en) 1999-12-31
EP0981375A1 (en) 2000-03-01
US20100076008A1 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
LT4736B (lt) Farmacinės kompozicijos, turinčios plazmos proteino
EP1604687B1 (en) Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer
CN110354073B (zh) 一种免疫抑制剂单克隆抗体的液体制剂
JP2002503704A (ja) ジデムニン（Ｄｉｄｅｍｎｉｎ）化合物の医薬製剤
EP1033372A1 (en) Compounds with antitumor activity
Janáky et al. Short-chain analogs of luteinizing hormone-releasing hormone containing cytotoxic moieties.
EP1701699B1 (en) Pharmaceutical compositions of an A2a receptor antagonist
WO2017191843A1 (ja) 高分子化薬物含有医薬組成物
Neuhofer Development of lipid based depot formulations using interferon-beta-1b as a model protein
Barthomeuf et al. Stabilization of Octastatin®, a somatostatin analogue: comparative accelerated stability studies of two formulations for freeze-dried products
HU223974B1 (hu) Plazma protein tartalmú gyógyszerkészítmények és eljárás előállításukra
MXPA00002561A (en) Pharmaceutical compositions containing plasma protein
JPWO1999025729A1 (ja) 抗腫瘍活性化合物

Legal Events

Date Code Title Description
PC9A Transfer of patents

Owner name: TEVA PHARMACEUTICAL WORKS PLC, HU

Effective date: 20060620

MK9A Expiry of a patent

Effective date: 20180917